In a first, FDA approves a gene therapy from a nonprofit The FDA on Tuesday approved Waskyra for a rare immune disease called Wiskott-Aldrich syndrome, for which patients have little options besides a bone marrow transplant.

Un jalon pour les maladies rares : la #FDA a approuvé Waskyra ( #Etuvetigène #Autotemcel), la 1ère #ThérapieGénique 🧬 pour le syndrome de #WiskottAldrich

#Waskyra a montré des réductions spectaculaires des infections graves et des épisodes de saignement.

endpoints.news/in-a-first-f...

FDA Flexibility Leads to First Approved Gene Therapy for Rare Blood & Immune System Disorder - MedCity News Waskyra is the first FDA-approved gene therapy for the rare disease Wiskott-Aldrich syndrome and the first such approved product from a non-profit applicant, Fondazione Telethon. Data from Waskyra’s p...

Waskyra est la 1ère #ThérapieGénique 🧬 approuvée par la #FDA 🇺🇸 pour la maladie rare du syndrome de #WiskottAldrich et le 1er par l'association #Telethon 🇫🇷

Les données de l'études de #Waskyra ont été présentées lors de la réunion annuelle de l’ #ASH25 🇺🇸

medcitynews.com/2025/12/gene...

Telethon Foundation Achieves FDA Approval for Waskyra Gene Therapy Targeting Wiskott-Aldrich Syndrome The FDA has approved Waskyra, a groundbreaking gene therapy for Wiskott-Aldrich Syndrome, bringing new hope to patients and advancing treatment options.

Telethon Foundation Achieves FDA Approval for Waskyra Gene Therapy Targeting Wiskott-Aldrich Syndrome #Italy #Milan #Waskyra #Wiskott-Aldrich-Syndrome #Gene-Therapy

Fondazione Telethon Celebrates FDA Approval of Waskyra™ Gene Therapy for WAS Treatment Fondazione Telethon has announced that the FDA approved Waskyra™, a groundbreaking gene therapy for Wiskott-Aldrich Syndrome (WAS), providing hope for patients.

Fondazione Telethon Celebrates FDA Approval of Waskyra™ Gene Therapy for WAS Treatment #USA #Rome #Fondazione_Telethon #Wiskott-Aldrich #Waskyra

FDA Approval of Waskyra™ Marks a Milestone in Wiskott-Aldrich Syndrome Treatment Fondazione Telethon proudly announces FDA approval for Waskyra™, a groundbreaking gene therapy for Wiskott-Aldrich Syndrome, offering new hope for patients.

FDA Approval of Waskyra™ Marks a Milestone in Wiskott-Aldrich Syndrome Treatment #Italy #Milan #Fondazione_Telethon #Wiskott-Aldrich #Waskyra

Fondazione Telethon Receives FDA Approval for Waskyra™ Gene Therapy for Wiskott-Aldrich Syndrome Fondazione Telethon has celebrated a significant achievement with the FDA's approval of Waskyra, a gene therapy for Wiskott-Aldrich Syndrome, offering new hope to patients.

Fondazione Telethon Receives FDA Approval for Waskyra™ Gene Therapy for Wiskott-Aldrich Syndrome #USA #Rome #Telethon #Waskyra #Wiskott-Aldrich_Syndrome

Telethon Foundation Receives Positive CHMP Opinion for Waskyra Gene Therapy to Combat Wiskott-Aldrich Syndrome The Telethon Foundation has announced a positive opinion from CHMP for Waskyra™, a gene therapy aimed at treating Wiskott-Aldrich Syndrome, a rare primary immunodeficiency disorder.

Telethon Foundation Receives Positive CHMP Opinion for Waskyra Gene Therapy to Combat Wiskott-Aldrich Syndrome #Italy #Rome #Wiskott-Aldrich #Waskyra #Telethon_Foundation

Fondazione Telethon Paves Way for Waskyra™ Gene Therapy Against Wiskott-Aldrich Syndrome Fondazione Telethon announces CHMP's positive opinion on Waskyra™, a gene therapy for Wiskott-Aldrich syndrome, advancing treatment options for patients.

Fondazione Telethon Paves Way for Waskyra™ Gene Therapy Against Wiskott-Aldrich Syndrome #Italy #Rome #Fondazione_Telethon #Wiskott-Aldrich #Waskyra